33 results about "Valganciclovir Hydrochloride" patented technology

The present invention relates to an amorphous form of valganciclovir hydrochloride and the pharmaceutical compositions thereof. The amorphous form can be directly prepared by spray-drying or azeotropic distillation of reaction mass. The amorphous form is useful in treating viral infections, for example, herpes simplex and cytomegalovirus.

The invention belongs to the field of pharmaceutical analysis, and particularly discloses a method for detecting HPLC of valganciclovir hydrochloride intermediate hydrolysate isomers. The method useschiral HPLC columns taking cellulose-3(3,5-dichloro phenyl amino formic ether) bonded silica gel as a stuffing bulking agent, and takes a mixed solution of hydrocarbon alkyl and alcohols as mobile phase, the column temperature is 20-40 DEG C, the flow velocity is 1.0-1.5 milliliters per minute, and the wave length is 250-260 nanometers. The method for detecting the HPLC of valganciclovir hydrochloride intermediate hydrolysate isomer has the advantages that the effective segregation of four isomers of the valganciclovir hydrochloride intermediate hydrolysate is achieved, the accuracy of the detection result is good, the sensitivity is high, the operation is simple and convenient, the cost is low, the analysis time is short, and guarantee is provided for the quality control of the valganciclovir hydrochloride intermediate hydrolysate.

The invention belongs to the technical field of analytical chemistry, and specifically discloses an HPLC analysis and detection method for valganciclovir hydrochloride impurities, more specifically, relates to an analysis and detection method for guanine, ganciclovir, and methoxymethylguanine Purine, ganciclovir 1‑N‑methylvaline ester, monoacetoxy ganciclovir, monochloroganciclovir, or drugs containing the impurities in the above 6 or their preparations. The solution to be tested is injected into a high-performance liquid chromatography column with phenylsilane-bonded silica gel as a filler, washed and separated with a mobile phase composed of an amine-containing inorganic salt solution and a chromatographically pure organic solvent, and then analyzed and detected by ultraviolet light. For the first time, this method creatively adds a certain concentration of ammonium acetate or ammonium formate into the mobile phase, which completely solves the difficult problem of separation between the main peak and impurity peaks and adjacent impurity peaks. It is easy to operate, high in resolution, high in sensitivity and good in accuracy. , after literature search, there is no similar literature report.

The present invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms.

A process for the preparation of valgancyclovir which comprises:a) reacting a compound of formula 7,in an aprotic solvent, in the presence of a condensing agent, with a compound of formula 8,wherein R1, and R2 may be, each independently, hydrogen, an halogen atom or an hydroxyl group; the double bond may either be in the E or Z configuration or a mixture thereof to yield a compound of formula 9b) mild hydrolysis of compound obtained in a) to give valgancyclovir.

The invention discloses a method for synthesizing valganciclovir hydrochloride, which comprises the following steps: with 1,3-dichloro-2-acetoxymethoxypropane as an initial raw material, preparing monochlorinated ganciclovir, and carrying out esterification, hydrolysis and deprotection salification to finally obtain the valganciclovir hydrochloride. The invention provides a synthesis method of siganciclovir hydrochloride, which avoids the problem of separation and conversion of N-7 and N-9 isomers in the diacetyl guanine condensation process. The method directly synthesizes monochlorinated ganciclovir without using ganciclovir, instead of the synthesis of monoacetyl ganciclovir in the prior art, so that the method avoids the problem of diester compound separation caused by ganciclovir residues, has the advantages of short process steps, simple operation, convenient purification and low cost, is beneficial to industrial production, and is suitable for synthesis of valganciclovir hydrochloride.

The invention provides a valganciclovir hydrochloride oral solution and a preparation method thereof, the valganciclovir hydrochloride oral solution is mainly composed of valganciclovir hydrochloride,a solubilizing system, a stabilizing system, a sweetener, an acidity regulator and a preservative; wherein the stabilizing system consists of a complexing agent, an antioxidant and a thickening agent; the contents of valganciclovir hydrochloride, the complexing agent, the antioxidant, the thickener, the sweetener, the acidity regulator and the preservative in the solubilizing system are respectively 7 to 12 percent (W / V), 0.08 to 0.12 percent (W / V), 0.12 to 0.18 percent (W / V), 0.15 to 0.25 percent (W / V), 0.06 to 0.12 percent (W / V), 18 to 22 percent (W / V) and 0.20 to 0.35 percent (W / V). According to the valganciclovir hydrochloride oral solution disclosed by the invention, the raw material medicines can be uniformly dispersed in the liquid solvent; according to the present invention, and are not hydrolyzed, such that the uniform and stable quality is provided, the xanthan gum is added to the acid solubilizing system so as to effectively reduce the degradation degree of valganciclovir hydrochloride, the valganciclovir hydrochloride degradation is less than 1.0% after the long-term sample reserving for 24 months, and the content uniformity RSD is less than 2%.

The invention discloses a valganciclovir hydrochloride preparation method, and belongs to the technical field of drug preparation. The preparation method comprises the steps: mixing a monoester substance, methanol and hydrochloric acid, dissolving, introducing into a material tank, introducing the dissolved substance in the material tank into a tubular reactor pre-filled with a catalyst through apump body, and enabling the material to circularly move in the tubular reactor through the other pump body, starting the circular reaction after compressed hydrogen is introduced, introducing nitrogeninto the tubular reactor after the reaction is finished, discharging the material into the receiving tank from the tubular reactor, and then impurity removal, decoloration and crystallization treatment is performed on the material to obtain a finished product. The tubular reactor is used as a main reaction place so that the reaction time can be greatly shortened, and the conversion efficiency isimproved; the catalyst filling in the reactor is easy to recover so that the cost can be saved; the automation degree is high, and the industrial continuous production requirement is met.

The invention belongs to the field of drug analysis, and specifically discloses an HPLC detection method for an enantiomer of a valganciclovir hydrochloride intermediate hydrolyzate. The method uses cellulose-tri(3,5-dichlorophenylamino Formic acid ester) bonded silica gel as a chiral chromatographic column with a mixed solution of alkanes and alcohols as the mobile phase, the column temperature is 20-40°C, the flow rate is 1.0-1.5ml / min, and the wavelength is 250-260nm . The invention realizes the effective separation of four isomers of valganciclovir hydrochloride intermediate hydrolyzate, has good detection result accuracy, high sensitivity, simple operation, low cost and short analysis time, and is valganciclovir hydrochloride The quality control of intermediate hydrolyzate provides guarantee.

The present invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms.

The invention provides a method for preparing and purifying Valganciclovir hydrochloride, characterized by using ganciclovir as a raw material and carrying out N,O triphenylmethyl protection, esterification, deprotection, salt transformation and recrystallization to obtain Valganciclovir hydrochloride. According to the invention, by using mixed anhydride method and avoiding using DCC, the posttreatment is simple; by using BOC protection to replace the CBZ protection used in the prior art, the reaction procedures are simplified, and the need for using noble metal Pd is avoided. The invention is suitable for industrial production.

The invention discloses a method for preparing valganciclovir hydrochloride I. The method comprises the following steps of: 1, dissolving phosphorus oxychloride into an inert solvent, and performing a reaction of the mixture and the alcoholic liquor to obtain phosphoryl halide II; 2, performing a reaction of ganciclovir and the phosphoryl halide II obtained in the step to obtain ganciclovir monoester III; 3, esterfying the ganciclovir monoester III in the step 2 and N-carbobenzoxy-L-valine to obtain ganciclovir diester IV; 4, acidizing the ganciclovir diester IV in the step 3 for dephosphorylation to obtain N-carbobenzoxy-L-valine ganciclovir monoester V; and 5, performing a hydrogenation reaction on the product in the step 4 to prepare the valganciclovir hydrochloride I. By the method, the ganciclovir monoester with high purity and yield can be produced, the post-processing is easy, and the post-processing difficulty is reduced.

The invention belongs to the field of drug analysis, and specifically discloses an HPLC detection method for valganciclovir hydrochloride intermediate condensate enantiomers. The method uses cellulose-tris(4-chloro-3-methylbenzene Base carbamate) coated silica gel as a chiral chromatographic column with a mixed solution of water and nitriles as the mobile phase, the column temperature is 10~20°C, the flow rate is 0.4~0.6ml / min, and the wavelength is 250 ~260nm. The invention realizes effective separation of four isomers of valganciclovir hydrochloride intermediate condensate, has good detection result accuracy, high sensitivity, simple operation, low cost and short analysis time, and is valganciclovir hydrochloride The quality control of intermediate condensate provides guarantee.

The invention discloses a novel valganciclovir hydrochloride synthesis method. The method includes: taking ganciclovir as a raw material, adopting ortho-ester for protecting a hydroxyl radical, then subjecting to condensation with N-carbobenzoxy-L-valine, and performing hydrolysis reaction to obtain N-carbobenzoxy valganciclovir; performing hydrogenation reduction reaction to obtain valganciclovir hydrochloride. The product purity reaches 99.0% or above and accords with United States Pharmacopeia standards.

The invention discloses a method for synthesizing valganciclovir hydrochloride. Using 1,3-dichloro-2-acetoxymethoxypropane as a starting material, monochloroganciclovir is prepared by esterification. , hydrolysis, deprotection into salt and finally obtain valganciclovir hydrochloride. The invention provides a method for synthesizing cganciclovir hydrochloride, which avoids the problem of separation and conversion of N-7 and N-9 isomers in the condensation process of diacetylguanine, and directly synthesizes monochlorovir without ganciclovir. Genanciclovir replaces the synthesis of monoacetyl ganciclovir in the prior art, and avoids the difficult problem of separation of diesters caused by residual ganciclovir. The method has short process steps, simple operation, easy purification and low cost. , conducive to industrial production, suitable for the synthesis of valganciclovir hydrochloride.

The invention provides a valganciclovir hydrochloride oral solution and a preparation method thereof. The valganciclovir hydrochloride oral solution mainly consists of valganciclovir hydrochloride, a solubilizing system, a stabilizing system, a sweetener, and an acidity regulator. The valganciclovir hydrochloride, the complexing agent, the antioxidant, the thickening agent , the content of the sweetener, the acidity regulator, and the preservative in the solubilization system are respectively 7-12% (W / V), 0.08-0.12% (W / V), 0.12-0.12% 0.18% (W / V), 0.15‑0.25% (W / V), 0.06‑0.12% (W / V), 18‑22% (W / V), 0.20‑0.35% (W / V). Each crude drug in the valganciclovir hydrochloride oral solution of the present invention can be uniformly dispersed in the liquid solvent without being hydrolyzed, so that it has uniform and stable quality, and the addition of xanthan gum in the acid solubilizing system can effectively reduce the For the degree of degradation of valganciclovir hydrochloride, the degradation of valganciclovir hydrochloride was less than 1.0% and the RSD of content uniformity was less than 2% as measured by long-term retention of samples for 24 months.

The invention provides a polymorphic substance of valganciclovir hydrochloride, and in particular relates to a crystal form A and a crystal form B. The invention further provides a preparation method of the polymorphic substance of valganciclovir hydrochloride, and an application of a medical composition containing the crystal form A and the crystal form B of polymorphic substance of valganciclovir hydrochloride in treating cytomegalovirus infection.